AAV1 Rep-Cap plasmid (serotype 1-specific AAV RC1 plasmids)

GeneMedi's AAV1 Rep-Cap plasmid supplies the AAV2 Rep (replication) proteins and the AAV1 capsid protein.

You can produce AAV1 particle in 293T cell line in high titer using GeneMedi's AAV1 Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.

The tissue tropism of AAV1 vector has been validated in neuron(CNS), heart, muscle, retina and Pancreas, with potential applications in tissue-specific gene therapy.

Target products collectionGo to AAV vector system >>



Product Description

Cat.NO Product Name Organization Type Price(In USD)
P-RC01 AAV1 Rep-Cap Plasmid
Academic 935
P-RC01 AAV1 Rep-Cap Plasmid
Industry R&D
(excluding
CRO&CDMO&CXO)
P-RC01 AAV1 Rep-Cap Plasmid
CRO&CDMO&
CXO&CMC&
Manufacturing company
P-RC01-Kan AAV1 Rep-Cap Plasmid(Kan resistance)
All
Currently, GeneMedi only offers amplification services for the Kan-resistant AAV Rep-Cap Plasmids and do not provide seed stocks.
P-PK01 AAV1 Vector System
1. AAV1 Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
Academic 2028
P-PK01 AAV1 Vector System
1. AAV1 Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
Industry R&D
(excluding
CRO&CDMO&CXO)
P-PK01 AAV1 Vector System
1. AAV1 Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
CRO&CDMO&
CXO&CMC&
Manufacturing company
P-PK01-Kan AAV1 Vector System(Kan resistance)
1. AAV1 Rep-Cap Plasmid(Kan resistance), 10mg
2. AAV Helper Plasmid(Kan resistance), 10mg
3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), 10mg
All
Currently, GeneMedi only offers amplification services for the Kan-resistant AAV Vector System and do not provide seed stocks.
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.
Terms of sale:
For Seed (5ug):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party.

For plasmid production&lification (≥10mg):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party.

Citation

Title Publication Date
Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides Nature 2023/12/13
Discovery of a potent allosteric activator of DGKQ that ameliorates obesity-induced insulin resistance via the sn-1, 2-DAG-PKCε signaling axis Cell Metabolism 2022/12/15
Histone demethylase JMJD3 downregulation protects against aberrant force-induced osteoarthritis through epigenetic control of NR4A1 International Journal of Oral Science 2022/7/14
Observing Extracellular Vesicles Originating from Endothelial Cells in Vivo Demonstrates Improved Astrocyte Function Following Ischemic Stroke via Aggregation-Induced Emission Luminogens ACS nano 2023/8/3
Genetically Engineered Hematopoietic Stem Cells Deliver TGF‐β Inhibitor to Enhance Bone Metastases Immunotherapy Advanced Science 2022/8/10
ATF3 -activated accelerating effect of LINC00941/lncIAPF on fibroblast-to-myofibroblast differentiation by blocking autophagy depending on ELAVL1/HuR in pulmonary fibrosis Autophagy 2022/4/15
Epigenetic controls of Sonic hedgehog guarantee fidelity of epithelial adult stem cells trajectory in regeneration Science Advances 2022/7/22
ETS-1 facilitates Th1 cell-mediated mucosal inflammation in inflammatory bowel diseases through upregulating CIRBP Journal of Autoimmunity 2022/8/1
Direct regulation of FNIP1 and FNIP2 by MEF2 sustains MTORC1 activation and tumor progression in pancreatic cancer Autophagy 2023/9/29
Circular RNA FEACR inhibits ferroptosis and alleviates myocardial ischemia/reperfusion injury by interacting with NAMPT Journal of Biomedical Science 2023/6/27


Validation data

Picture loading failed.
Figure. Selected transduction results of AAV in vitro (in 293T cell line)

Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×1012 vg/ml
Cells: HEK-293T
MOI: MOI=1×104
Determine assay: 36 hours post infection, immunofluorescence microscopy


Associated products and services


Products & Service Products & Service Information
AAV Packaging service Detail
Promise-ORF™ viral CDNA library Detail
Plasmid DNA Rapid Preparation Service Detail